A5060133051- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Parkinson's Disease Mechanisms and Treatments
- Neuroblastoma Research and Treatments
- Advanced X-ray and CT Imaging
- Urologic and reproductive health conditions
- Lung Cancer Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Amyotrophic Lateral Sclerosis Research
- Colorectal Cancer Surgical Treatments
- Neurogenetic and Muscular Disorders Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Radiation Dose and Imaging
- Bone Tumor Diagnosis and Treatments
- Metastasis and carcinoma case studies
- Cardiac tumors and thrombi
- Genetic Neurodegenerative Diseases
University of Turin
2020-2022
University of Bologna
2015-2020
Policlinico S.Orsola-Malpighi
2014-2020
University of California, Los Angeles
2018-2020
Affidea
2020
Molecular Theranostics (United States)
2020
Los Angeles Medical Center
2018
(1.1) to evaluate the association between baseline 18F-FDG PET/CT semi-quantitative parameters of primary lesion with progression free survival (PFS), overall (OS) and response immunotherapy, in advanced non-small cell lung carcinoma (NSCLC) patients eligible for immunotherapy; (1.2) application radiomics analysis identify features predictive (1.3) if tumor burden assessed by (N M factors) is associated PFS OS.we retrospectively analyzed clinical records NCSLC (stage IIIb/c or stage IV)...
This study was performed to investigate the role of (68)Ga-DOTANOC SUVmax as a potential prognostic factor in patients with pancreatic neuroendocrine tumor (pNET).Among who underwent PET/CT, we retrospectively collected data those had G1 or G2 pNET (2010 World Health Organization classification), presented disease on PET/CT and CT, at least 6 mo follow-up. Patients multiple endocrine neoplasia were excluded.Overall, 43 included. No significant differences observed respect sex, syndrome,...
Abstract Background To determine whether artificial intelligence (AI) processed PET/CT images of reduced by one-third 18-F-FDG activity compared to the standard injected dose, were non-inferior native scans and if so assess potential impact commercialization. Materials methods SubtlePET™ AI was introduced in a center Italy. Eligible patients referred for 18F-FDG prospectively enrolled. Administered two-thirds dose. Patients underwent one low-dose CT two sequential PET scans; “PET-processed”...
Abstract Objective To identify the impact of segmentation methods and intensity discretization on radiomic features (RFs) extraction from 68 Ga-DOTA-TOC PET images in patients with neuroendocrine tumors. Methods Forty-nine were retrospectively analyzed. Tumor contouring was performed manually by four different operators a semi-automatic edge-based (SAEB) algorithm. Three SUV max fixed thresholds (20, 30, 40%) applied. Fifty-one RFs extracted applying two rescale factors for gray-level...
Objective We aimed at evaluating the brain metabolic features of fused in sarcoma amyotrophic lateral sclerosis ( FUS ‐ALS) compared with sporadic ALS (sALS), using 2‐[fluorine‐18] fluoro‐2‐deoxy‐D‐glucose positron emission tomography (2‐[ 18 F]FDG‐PET). Methods employed 2‐sample t ‐test model SPM12, implemented MATLAB, to compare 12 ‐ALS cases 40 healthy controls (HC) and 48 sALS, randomly collected from series patients who underwent 2‐[ F]FDG‐PET Center Turin (Italy) diagnosis 2009 2019....
MRI studies reported that ALS patients with bulbar and spinal onset showed focal cortical changes in corresponding regions of the motor homunculus. We evaluated capability brain 2-[18F]FDG-PET to disclose metabolic features characterizing pure or impairment.We classified as (PB) a normal score items ALSFRS-R, (PS) at time PET. Forty healthy controls (HC) were enrolled. compared PB PS, each patient group HC. Metabolic clusters showing statistically significant difference between PS tested...
We investigated sex-related brain metabolic differences in Amyotrophic Lateral Sclerosis (ALS) and healthy controls (HC).
Abstract Introduction This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [ 18 F]FDG PET/CT as tool for early response assessment neoadjuvant chemotherapy (neo-CTX). Methods Bone or soft tissue (1) baseline within 4 weeks prior the start of neo-CTX (PET1), (2) interim (6 after (PET2), (3) evaluation by histology MRI, and (4) definitive therapy (surgery radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV TLG)...
The purpose of this study was to evaluate <sup>18</sup>F-FDG PET/CT as an early and late interim imaging biomarker in patients with pancreatic ductal adenocarcinoma who undergo first-line systemic therapy. <b>Methods:</b> This a prospective, single-center, single-arm, open-label (IRB12-000770). Patient receiving chemotherapy were planned baseline PET/CT, PET/CT. Cutoffs for metabolic radiographic tumor response assessment selected established by receiver-operating-characteristic analysis...
To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients.Forty four patients, who underwent before (28/44) (16/44), were retrospectively analyzed. Whole-body per-district metabolic volume (MTV) total lesion glycolysis (TLG) calculated. Therapy response was assessed according to RECIST 1.1 on CT scan at 3 (early) 12 (late) months. PET compared using...
Background/Aim: To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients. Materials Methods: 44 patients who underwent before (28/50) (16/50) were retrospectively analyzed. Whole-body per-district metabolic volume (MTV) total lesion glycolysis (TLG) calculated. Therapy response was assessed according to RECIST 1.1 on CT scan at 3 (early) 12 (late) months....
Abstract BackgroundTo determine whether artificial intelligence (AI) processed PET/CT images of reduced by 33% administered 18-F FDG activity acquired in a single center, were non-inferior to native scans and if so assess the potential impact commercialization. MethodsSubtlePET™ AI was introduced center Italy. Eligible patients referred for 18F-FDG prospectively enrolled. Administered two-thirds standard dose. Patients underwent one low-dose CT two sequential PET scans; ‘PET-processed’ with...
Abstract Background To determine whether artificial intelligence (AI) processed PET/CT images of reduced by 33% administered 18-F FDG activity acquired in a single center, were non-inferior to native scans and if so assess the potential impact commercialization. Methods SubtlePET™ AI was introduced center Italy. Eligible patients referred for 18F-FDG prospectively enrolled. Administered two-thirds standard dose. Patients underwent one low-dose CT two sequential PET scans; ‘PET-processed’...